Plasma Articles
A potential solution for CIDP patients with these IVIG-related issues is self-administered subcutaneous immune globulin.
The success of IG manufacturing assures that today and in the future, patients in need have access to this unique therapeutic.
Researchers are taking a closer look at intravenous immune globulin for its potential to stop the progression of multiple complex conditions from lupus to multiple sclerosis.
The plasma donor is the first vital part of the process to produce safe and effective plasma protein therapeutics, and the industry prioritizes the safety and health of its plasma donors.
